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Background/aim: Community-onset urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing
Escherichia coli have increased in many parts of the world. This study aimed to determine the prevalence and risk factors for communityonset UTI caused by ESBL-producing E. coli.
Materials and methods: This prospective cohort study was conducted between January 2012 and March 2014 in cases of communityonset UTI caused by E. coli. Patients with UTI due to ESBL-producing E. coli and patients with UTI due to non-ESBL-producing E. coli
were compared to identify risk factors for ESBL-producing E. coli in the community.
Results: A total of 305 patients (116 males [46.4%]; mean age: 57.76 ± 18.06 years) were included in the study. Among these patients, 154
(50.5%) were infected with ESBL-producing E. coli. In multivariate analysis, the healthcare-associated UTI (odds ratio [OR]: 1.80; 95%
confidence interval [CI]: 1.02–3.18; P = 0.041), upper urinary tract infection (OR: 3.05; 95% CI: 1.76–5.29; P < 0.0001), use of antibiotics
in the preceding 6 months (OR: 2.28; 95% CI: 1.21–4.30; P = 0.011), and having two or more risk factors (OR: 4.03; 95% CI: 1.73–9.35;
P = 0.001) were the significant factors associated with increased risk of community-onset UTIs due to ESBL-producing E. coli.
Conclusion: The increasing prevalence of ESBL-producing E. coli makes it difficult to decide the empirical therapy in UTIs, especially in
patients with two or more of the risk factors. A better understanding of the epidemiology and risk factors associated with communityonset UTIs due to ESBL-producing E. coli may have significant implications in decision-making for empirical antimicrobial treatment.
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1. Introduction
Urinary tract infections (UTIs) are the most common
community-onset infections in the adult population
in many parts of the world. Clinical manifestations
of community-onset UTIs range from asymptomatic
bacteriuria to acute pyelonephritis with sepsis [1,2].
The major UTI pathogen is Escherichia coli, and there
is increasing multidrug resistance in the isolates from
community-onset infections. Multidrug resistance of
these isolates is frequently associated with the presence
of extended-spectrum β-lactamase (ESBL) genes [3,4].
ESBL-producing isolates are resistant to all penicillins,
cephalosporins, and aztreonam, combined with high
resistance rates to fluoroquinolones and trimethoprim/
sulfamethoxazole (TMP-SMX) [5]. Multidrug resistance
of ESBL-positive E. coli makes it more difficult to decide
the antibiotic treatment in community-onset UTI and

increases the risk of treatment failure. Early initiation
of appropriate empirical therapy reduces mortality,
especially in life-threatening UTIs [6]. Therefore, a better
understanding of the risk factors for community-onset
UTIs caused by ESBL-positive E. coli will guide clinicians
in choosing appropriate empirical therapy. Also, it will
ensure that measures are taken to reduce risk factors for
these resistant infections.
For this reason, we aimed to determine the prevalence
and risk factors for community-onset UTI caused by
ESBL-producing E. coli.
2. Materials and methods
2.1. Study population and data collection
This prospective cohort study was conducted between
January 2012 and March 2014 in cases of communityonset UTI caused by E. coli. Demographic characteristics,
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underlying diseases, and clinical signs and symptoms
of the patients, as well as microbiological data, were
recorded. This study was conducted with the approval of
the Medical Ethics Committee of Pamukkale University
(date: 17 January 2012; resolution number: 02) and
adhered to the principles of the Declaration of Helsinki.
Individual informed consent was obtained from all study
participants.
Patients admitted with clinical signs and/or symptoms
of UTIs (e.g., fever >38 °C, urgency, frequency, dysuria, or
suprapubic tenderness) with no other recognized cause,
pyuria (i.e. urine specimen with ≥10 white blood cells/
mm3), and a positive urine culture were enrolled in the
study [7].
UTI was defined as “community-onset” when the
infection occurred among nonhospitalized patients or
<48 h after hospitalization. Community-onset UTIs
include community-acquired UTIs and healthcareassociated UTIs [7]. Therefore, we included healthcareassociated UTIs according to previously published criteria:
hospitalization in an acute care hospital for two or more
days in the previous 90 days; residence in a nursing home
or a long-term care facility; received intravenous therapy
at home or in a day hospital; hemodialysis treatment;
intravenous chemotherapy 30 days before the infection;
received wound care or specialized nursing care in the
preceding 30 days; presence of long-term indwelling
urethral catheters or an invasive urinary tract procedure
in the previous 30 days [8].
2.2. Microbiological analysis
Urine specimens were obtained from either first cleancatch midstream urine or urinary catheters. The isolated
bacteria were identified by conventional methods in the
microbiology laboratory. Positive urine cultures were
defined when the bacterial growth was ≥103 colony
forming units (CFU)/mL [9]. ESBL determination was
performed phenotypically with ceftazidime/ceftazidime
clavulanate and cefotaxime/cefotaxime clavulanate disks,
as recommended by the Clinical and Laboratory Standards
Institute (CLSI) [10]. Antimicrobial susceptibility testing
was performed using the disk diffusion method, according
to the CLSI standards.
Patients with UTI due to ESBL-producing E. coli and
non-ESBL-producing E. coli were compared in terms of
demographic characteristics, underlying diseases, and
microbiological data to identify risk factors for ESBLproducing E. coli in the community.
2.3. Statistical analysis
Continuous variables were compared by independent
samples t-test, and categorical variables were compared
by chi-square test or Fisher’s exact test for association.
Differences were considered statistically significant at P
< 0.05. Statistical calculations were performed using SPSS

17.0 for Windows (SPSS Inc., Chicago, IL, USA). In order
to analyze the effect of the number of risk factors on ESBLproducing E. coli, we separated the patients based on
existing risk factors. Patients with no risk factor, one risk
factor, and two or more risk factors were analyzed.
Backward stepwise multiple logistic regression was
performed to identify the risk factors for community-onset
UTI caused by ESBL-producing E. coli as the dependent
variable. However, we did not include the risk factors that
were also in the definition of healthcare-associated UTIs
in the multivariate analysis.
3. Results
A total of 305 patients (116 males (46.4%); mean age: 57.76
± 18.06 years; range: 16–87 years) were included in the
study. Among these patients, 154 (50.5%) were infected
with ESBL-producing E. coli.
Being male, old age (≥55 years), hospitalization within
3 months, use of antibiotics within the previous 6 months,
healthcare-associated UTI, upper UTI, frequent UTIs
(>3 times/year), presence of indwelling urethral catheter,
renal failure, and neoplasia were significant risk factors
for ESBL-producing E. coli among community-onset UTI
cases in univariate analysis (P < 0.05). Moreover, patients
with two or more risk factors were more likely to have
ESBL-producing E. coli. ESBL positivity was lower in
patients with one risk factor or no risk factors (P < 0.05)
(Table 1). Healthcare-associated UTI was seen in 142/305
(46.6%) patients; indwelling urethral catheter use was
the most common reason, with a rate of 102/142 (71.8%)
patients.
In multivariate analysis, factors associated with an
increased risk of community-onset UTIs due to ESBLproducing E. coli included healthcare-associated UTI
(odds ratio [OR]: 1.80; 95% confidence interval [CI]:
1.02–3.18; P = 0.041), upper urinary tract infection (OR:
3.05; 95% CI: 1.76–5.29; P < 0.0001), use of antibiotics in
the preceding 6 months (OR: 2.28; 95% CI: 1.21–4.30; P =
0.011), and having two or more risk factors (OR: 4.03; 95%
CI: 1.73–9.35; P = 0.001) (Table 2). Regarding antibiotic
class, previous use of cephalosporin and fluoroquinolones
was associated with ESBL-producing E. coli (respectively
P < 0.001, P = 0.019). There was no correlation between
the use of beta-lactam-beta-lactamase inhibitors and ESBL
positivity (P = 0.16) (Table 1).
ESBL-producing E. coli isolates had more non-betalactam antibiotic resistance than non-ESBL-producing
E. coli isolates. The resistance rates for ciprofloxacin were
91.6% and 30.5% (P < 0.0001), for TMP-SMX were 65.4%
and 35.8% (P < 0.0001), for gentamicin were 64.3% and
7.3% (P < 0.001), for amoxicillin-clavulanate were 99.4%
and 23.8% (P < 0.0001), for piperacillin-tazobactam were
19.5% and 4% (P < 0.0001), and for nitrofurantoin were
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Table 1. Characteristics of community-onset UTI caused by ESBL-producing Escherichia coli.
ESBL-positive E. coli, n=154 (%) ESBL-negative E. coli, n=151 (%) P-value
Sex, male, n = 116 (%)

73 (47.4)

43 (28.5)

0.01

Age ≥55 years
Hospitalization within 6 months
Length of hospital stay, days, mean ± SD

101 (65.6)
73 (47.4)
16.86 ± 18.07

78 (51.7)
22 (14.6)
15.95 ± 15.71

0.014
<0.0001
0.83

Use of antibiotics within previous 6 months
Fluoroquinolones
Cephalosporins
Beta-lactam-beta-lactamase inhibitors

62 (40.3)
24 (16.0)
28 (18.3)
6 (3.9)

20 (13.2)
11 (7.3)
6 (4.0)
2 (1.3)

<0.0001
0.019
<0.001
0.16

Healthcare-associated UTI

98 (63.6)

44 (29.1)

<0.0001

Upper UTI

94 (61.0)

36 (23.8)

<0.0001

Frequent UTIs (>3 times/year)

45 (29.2)

16 (10.6)

<0.0001

Indwelling urethral catheter

75 (48.7)

30 (19.9)

<0.0001

Diabetes mellitus

41 (26.6)

45 (29.8)

0.53

Renal failure

54 (35.1)

23 (15.2)

<0.0001

Nephrolithiasis

28 (18.2)

25 (16.6

0.708

Renal transplantation

6 (3.9)

2 (1.3)

0.160

Use of corticosteroid

11 (7.1)

10 (6.6)

0.858

Chronic obstructive lung disease

13 (8.4)

9 (6.0)

0.402

Neoplasia

37 (24.0)

19 (12.6)

0.01

Chemotherapy

6 (3.9)

5 (3.3)

0.784

Menopause, n = 189 (%)*

57 (70.4)

72 (66.7)

0.588

Prostate benign hypertrophy, n = 116 (%)#
No risk factor
One risk factor
Two or more risk factors

48 (64.9)
7 (4.5)
4 (2.6)
146 (94.8)

27 (62.8)
20 (13.2)
24 (15.9)
106 (70.2)

0.822
0.007
<0.0001
<0.0001

*: Univariate analysis was performed in women.
#
: Univariate analysis was performed in men.
Table 2. Multivariate analysis of risk factors for community-onset UTI caused by ESBL-producing
Escherichia coli.
Odds ratio 95% Confidence interval P-value
Use of antibiotics within previous 6 months

2.28

1.21–4.3

0.011

Healthcare-associated UTI

1.80

1.02–3.18

0.041

Upper UTI

3.05

1.76–5.29

<0.0001

Two or more risk factors

4.03

1.73–9.35

0.001

9.7% and 5.3% (P = 0.193), respectively. Fosfomycin
resistance was found only in one ESBL-producing E. coli
isolate, and there was no resistance to fosfomycin in nonESBL-producing E. coli isolates (Figure).
4. Discussion
ESBL-producing E. coli is a precariously increasing
pathogen among community-onset UTIs. The ESBL
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prevalence rate is variable in different geographical
regions. For instance, in Norway, it is lower than 2%, but it
can also be very high, over 74%, like in Iran [11,12]. ESBLproducing E. coli is responsible not only for healthcareassociated but also for community-acquired UTI even in
countries with low antibiotic use [5,11,13], and multidrug
resistance makes it more difficult to decide the appropriate
antibiotic treatment.
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Figure. Antimicrobial susceptibility rate (%) of ESBL-positive and -negative Escherichia coli.

Our results revealed that the ESBL-producing E. coli
rate was 50.5% in patients with community-onset UTI,
and 63.6% of ESBL (+) patients were diagnosed as having
healthcare-associated UTIs, while only 29% of ESBL (-)
patients had healthcare-associated UTIs. This prevalence
seems to be higher than in previous studies [3,14]. In a
study from Turkey, the SMART study, the rate of ESBLpositive E. coli was much higher in healthcare-associated
than community-acquired UTIs during 2011 and 2012,
at 50% and 38%, respectively [14]. Another study from
Turkey reported a similar ESBL-producing E. coli rate in
2006, as 36.7%, among patients with community-acquired
UTIs, but ESBL-producing E. coli rates were not given for
healthcare-associated UTIs [3]. The higher rates of ESBLproducing E. coli in community-onset UTIs in our study
can be related to higher rates of healthcare-associated
UTIs and also a different study period.
The major independent risk factors for ESBL positivity
in our series were the presence of healthcare-associated
UTIs, upper urinary tract infection, use of antibiotics
in the preceding 6 months, and having two or more risk
factors. Healthcare-associated UTIs were associated with
an increased risk for ESBL positivity in our analysis.
Similarly, previous studies showed that ESBL-producing E.
coli was more frequent in patients with several healthcareassociated infections including UTIs [15–18]. Indwelling
urethral catheter use was the most common reason for
healthcare-associated UTI [19,20]. Similarly, the rate of

indwelling urethral catheter use was as high as 71.8% in
healthcare-associated UTIs in our series.
Our results revealed that there is a threefold increased
risk of ESBL-producing E. coli in upper UTI cases. We
did not come across a study that showed a relationship
between upper UTIs and ESBL positivity in our literature
review. However, it may be suggested that ESBL-producing
E. coli is a frequent causative agent in upper UTIs due to
a requirement for more frequent hospitalizations, more
complications, and the presence of different underlying
risk factors in this patient group.
We also found the number of risk factors for ESBLpositive E. coli to be important. ESBL positivity was lower
in patients with no risk factors or one risk factor, which
included being male, old age (≥55 years), use of antibiotics
within the previous 6 months, healthcare-associated UTI,
upper UTI, frequent UTIs (>3 times/year), renal failure,
and neoplasia. In contrast, patients with two or more risk
factors were more likely to have ESBL-producing E. coli.
When we did not include the presence of two or
more risk factors in multivariate analysis, we found that
being 55 years of age or older was an independent risk
factor. In elderly patients, additional comorbid issues,
hospital admission rates, and infectious diseases are
more frequent. Antimicrobial drug use, and therefore
a greater risk of acquiring antibiotic-resistant bacterial
infections, is more frequent among older patients [21].
As in our study, older age and previous use of antibiotics
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were reported as risk factors for ESBL-positive E. coli in
previous studies [15,22–25]. In terms of antibiotic class,
previous use of cephalosporin and fluoroquinolones was
associated with ESBL-producing E. coli. Although the use
of fluoroquinolone and cephalosporin was reported to be
an independent risk factor in many studies [11,18,26,27],
the use of fluoroquinolone was not associated with ESBL
positivity in some studies [2,25].
Extended-spectrum beta-lactamase-producing E. coli
is not only resistant to beta-lactam antibiotics; there is also
a higher rate of coresistance to many antibiotic groups,
particularly quinolones, TMP-SMX, and aminoglycosides
[24]. Similar to previous reports [12,26,28], our results
showed that ESBL-producing E. coli isolates had more
antibiotic resistance than did non-ESBL-producing
E. coli isolates. Particularly, amoxicillin-clavulanate,
ciprofloxacin, TMP-SMX, and gentamicin resistance
was very significant in ESBL-producing E. coli isolates.
Both ESBL-positive and ESBL-negative E. coli isolates
remain highly susceptible to carbapenems, fosfomycin,
and nitrofurantoin. However, the amoxicillin-clavulanate
resistance was higher in the ESBL-positive group than in
the studies mentioned above. In a multinational survey,

ESBL-producing Enterobacteriaceae isolates from Turkey
were more likely to be resistant to amoxicillin-clavulanate
than isolates from other regions [23].
A limitation of the present study is the absence of
molecular strain typing of ESBL-positive E. coli isolates.
However, the most prevalent type was CTXM-15 among
these isolates, also reported in previous studies from
Turkey [3,29].
This study revealed that the ESBL rate of E. coli
isolated from community-onset UTI cases was high in
Turkey. The major risk factors for ESBL-producing E. coli
were the presence of a healthcare-associated UTI, upper
urinary tract infection, use of antibiotics in the preceding
6 months, and having two or more risk factors. The
increasing prevalence of ESBL-producing E. coli makes
it difficult to decide the empiric therapy in UTI cases,
especially in patients with two or more of the risk factors.
Therefore, a better understanding of the epidemiology and
risk factors of community-onset UTIs caused by ESBLproducing E. coli may have significant implications for the
choice of empiric antimicrobial treatment. Considering
the risk factors in this patient group can increase treatment
success.
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